SANTA CLARA, Calif. & NASHVILLE, Tenn.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) and Vanderbilt-Ingram Cancer Center announced today that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, researchers at Vanderbilt-Ingram and Vanderbilt University Medical Center will use Affymetrix GeneChip® microarray technology to develop new applications for translational research projects, focusing on disease areas such as cancer and HIV/AIDS.
